Decitabine promotes degradation of DNMT1 and EZH2 via the ubiquitination pathway and inhibits colorectal cancer progression.
- DOI
- 10.1007/s13402-025-01136-8
- Published
- 2025 Dec 29
- Container
- Cellular oncology (Dordrecht, Netherlands)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s13402-025-01136-8,
title = {Decitabine promotes degradation of DNMT1 and EZH2 via the ubiquitination pathway and inhibits colorectal cancer progression.},
author = {Peng XM and Shi XP and Chen H and Cao LY and Zuo HJ and Guo JQ and Jiang N and Luo XY},
year = {2025},
journal = {Cellular oncology (Dordrecht, Netherlands)},
doi = {10.1007/s13402-025-01136-8},
url = {https://doi.org/10.1007/s13402-025-01136-8}
}RIS
TY - JOUR TI - Decitabine promotes degradation of DNMT1 and EZH2 via the ubiquitination pathway and inhibits colorectal cancer progression. AU - Peng XM AU - Shi XP AU - Chen H AU - Cao LY AU - Zuo HJ AU - Guo JQ AU - Jiang N AU - Luo XY PY - 2025 JO - Cellular oncology (Dordrecht, Netherlands) DO - 10.1007/s13402-025-01136-8 UR - https://doi.org/10.1007/s13402-025-01136-8 ER -
APA
XM, P., XP, S., H, C., LY, C., HJ, Z., JQ, G., N, J., & XY, L. (2025). Decitabine promotes degradation of DNMT1 and EZH2 via the ubiquitination pathway and inhibits colorectal cancer progression.. Cellular oncology (Dordrecht, Netherlands). https://doi.org/10.1007/s13402-025-01136-8
Source records
- pubmed · retrieved 2026-09-26T22:29:08.674Z